By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Feb 4 (Reuters) - Novo Nordisk's shares tumbled as much as 20% ...

The stock tumbled 19% at the opening bell in Copenhagen after its outlook for the year ahead disappointed investors.

COPENHAGEN, Feb 4 () - Novo Nordisk CEO Mike ​Doustdar said on ‌Wednesday that the price reductions ‌for its obesity drug ...

Chief Executive Officer Mike Doustdar warned, “People should expect that it goes down before it comes back up,” citing pressure from significantly lower US pricing on its blockbuster weight-loss drug ...

The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key ...

Novo Nordisk A/S faces a margin crisis as oral Wegovy hits injectable profits. Click for this post-earnings update and see ...

Novo Nordisk said it expects lower sales this year as the Danish drugmaker takes stock of lower prices for Ozempic and Wegovy ...

Shares in the Danish pharmaceuticals group Novo Nordisk plunged Wednesday after the maker of Ozempic and Wegovy anti-obesity ...

For full-year 2025, sales are projected at DKK 307.62B, up from DKK 290.4B in 2024, with Wegovy contributing DKK 78.28B and Ozempic DKK 124.87B. EPS is forecast at DKK 23.28, compared with DKK 22.63 ...

Novo Nordisk, the maker of blockbuster weight-loss drug Wegovy, has warned that profits and sales could fall by as much as 13 ...

The maker of Ozempic is facing stiff competition from rival obesity drug companies, as well as unproven knock-offs from China ...

COPENHAGEN, Feb 3 (Reuters) - Wegovy maker Novo Nordisk expects a decline in sales this year, it said on Tuesday, a new ...